Dr Keating Email Interview, page-79

not a serious competitor in my opinion

1. Needs FDA approval to be a serious competitor
2. Requires a purchase of device
3. Clinician would be wary of diagnosing from an "off the shelf gadget"
4. Resapp scope of disease diagnosis and management will only increase
5 Resapp can distinguish between what type of pneumonia, with preliminary results for separation of bacterial and atypical pneumonia from viral pneumonia with accuracy of 89% and 92% respectively

6. I believe they will approach FDA approval for numerous diseases once the initial application has been completed. For the diagnosis of croup, viral pneumonia, bronchiolitis and upper respiratory tract infections (URTIs) ResApp’s algorithms achieved accuracy levels between 90% and 98% on the larger dataset.

Now they have the funds its only a matter of time Resapp have application for CE Mark for Europe and Asia is next.....